In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, highlights where regulatory agencies currently stand on sustainability in clinical trials and how pharma companies are looking to reduce their carbon footprint.
In a recent video interview with Applied Clinical Trials, Theirry Escudier, Portfolio Lead, Pistoia Alliance, discussed the alliance’s newest initiative to assess the carbon footprint of clinical trials. The initiative aims to answer whether decentralized clinical trials positively or negatively impact carbon footprints. Escudier also discussed how clinical research stakeholders are slowly beginning to adopt more sustainability practices, focusing on reducing waste and costs.
ACT: How will this initiative aid in regulators’ increased demand for sustainability and transparency?
Escudier: In a way, it's beyond, I would say, the regulatory requirement, because, as such, regulatory agencies, that is to say those health regulatory agencies looking for new drug submissions are not yet asking for any data on sustainability itself. This is more of a high-level request from in particular Europe, we have some very ambitious goals to reduce the carbon footprint in order to have less impact on the climate change. Some of the goals have been set up by the European Commission, the European Parliament, the National Parliament, and the national government, so there is, I would say, an overall trend within the industry, not specifically in the pharmaceutical world. Therefore, currently, I don't think there is any requirement from specific regulatory agencies such as the EMA, MHRA, or the FDA. It may come one day or the other, so that's why we have to be prepared, but it's more the voluntary approach from the pharmaceutical industry to consider that they want to also behave even beyond the fact that, as you know, the pharmaceutical industry is working to provide new drugs for saving lives, I would say, reducing the pain, maintaining people in good health, and at the same time, we know that our processes, whatever they are coming from R&D or from the industry, are producing carbon footprint, therefore may have an impact on the climate change, so therefore it's even more important that as an industry as a whole, the pharmaceutical companies are looking to how to reduce the production of carbon in order that in fact, not to offset the benefit of the new drugs, or the drugs we are currently, I would say offering to the to the patient.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.